Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cimetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | ATP4A | P20648 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ATP4B | P51164 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cimetidine SCHEMBL27313058 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL3735476 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL28681657 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL534523 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL1736444 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL28666399 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL28492534 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL1736443 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL22127097 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR | |
| Cimetidine SCHEMBL28689625 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6HRH2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242919-A1 | NOVEL BINDING PROTEINS FOR HYALURONIC ACID | NAVIGO PROTEINS GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| US-8728528-B2 | Process for preparing microparticles having a low residual solvent volume | EVONIK CORPORATION (US) | 2014-05-20 | — | — | US | claimed |
| CN-103536570-A | Cimetidine composition lyophilized oral-disintegration tablets | HAINAN WEIKANG PHARM QIANSHAN | 2014-01-29 | — | — | CN | claimed |
| EP-2222281-A1 | PROCESS FOR PREPARING MICROPARTICLES HAVING A LOW RESIDUAL SOLVENT VOLUME | Surmodics Pharmaceuticals, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| WO-2009085952-A1 | PROCESS FOR PREPARING MICROPARTICLES HAVING A LOW RESIDUAL SOLVENT VOLUME | BROOKWOOD PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090162407-A1 | PROCESS FOR PREPARING MICROPARTICLES HAVING A LOW RESIDUAL SOLVENT VOLUME | EVONIK OPERATIONS GMBH (DE) | 2009-06-25 | — | — | US | claimed |
| WO-2009071188-A1 | METHOD AND SYSTEM FOR CONFIGURING A CONSOLIDATED SOFTWARE APPLICATION | ROCHE DIAGNOSTICS GMBH (DE) | 2009-06-11 | — | — | WO | claimed |
| WO-2006038988-A1 | CHEWABLE ELECTROLYTE TABLET | PAL LABORATORIES, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| US-20060068005-A1 | Chewable electrolyte tablet | PAL LABORATORIES, INC. (US) | 2006-03-30 | — | — | US | claimed |
| EP-0746342-B1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | BIOVAIL TECH LTD (US) | 2002-08-14 | — | — | EP | claimed |
| US-5622709-A | Cimetidine-phenol pharmaceutical composition | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-22 | — | — | US | claimed |
| WO-1994016695-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING CIMETIDINE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-04 | — | — | WO | claimed |
| EP-0320551-A1 | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2 receptor blockers | Bristol-Myers Company (US) | 1989-06-21 | — | — | EP | claimed |
| US-4757060-A | Analgesic, H1, H2 receptor blockers | BRISTOL-MYERS COMPANY (US) | 1988-07-12 | — | — | US | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3921420-B1 | DRUG DELIVERY COMPOSITIONS FOR OCULAR ADMINISTRATION OF THERAPEUTICS AND METHODS OF USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| WO-1984001105-A1 | DIETARY AND PHARMACEUTICAL USES OF METHYLSULFONYLMETHANE AND COMPOSITIONS COMPRISING IT | HERSCHLER R J | 1984-03-29 | — | — | WO | disclosed |
| EP-0103836-A2 | Dietary and pharmaceutical compositions comprising methylsulfonylmethane | Herschler, Robert J. (US) | 1984-03-28 | — | — | EP | disclosed |
| US-4303406-A | WASHING MACHINE WHICH MONITORS AND ADJUSTS WATER LEVEL AFTER LOADING; PROGRAMMABLE | THE MAYTAG COMPANY (US) | 1981-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | HRH2 3614/4885CYP3A4 3408/4885CYP2D6 3089/4885 |
| US-20090162407-A1 | PROCESS FOR PREPARING MICROPARTICLES HAVING A LOW RESIDUAL SOLVENT VOLUME | EXOSC9, PHOSPHO1, PLTP | HRH2 3833/4885CYP3A4 2038/4885CYP2D6 2431/4885 |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | PHAX, RNMT, PRKCZ | HRH2 4400/4885CYP3A4 4876/4885CYP2D6 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.